Seroprotection rate in adults after 1-dose, 2-dose, and 3-dose series of a reduced-diphtheria-tetanus toxoid vaccine (Td) during a diphtheria outbreak in Thailand

被引:2
|
作者
Suntarattiwong, Piyarat [1 ,2 ]
Vandepitte, Warunee Punpanich [1 ,2 ]
Singhamatr, Pon [3 ]
Chotpitayasunondh, Tawee [1 ]
机构
[1] Queen Sirikit Natl Inst Child Hlth, 420-8 Rajavithi Rd, Bangkok 10400, Thailand
[2] Rangsit Univ, Coll Med, Bangkok, Thailand
[3] Queen Sirikit Natl Inst Child Hlth, Dept Pathol, Bangkok, Thailand
关键词
Diphtheria outbreak; Diphtheria toxoid vaccine; Diphtheria; Adult vaccination; Thailand immunization program; SEROPREVALENCE; IMMUNITY; CHILDREN;
D O I
10.1016/j.vaccine.2020.01.040
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To evaluate seroprotection of different dosing strategies of reduced-diphtheria-tetanus-toxoid vaccine (Td) for adults during a diphtheria outbreak in Thailand, we enrolled 160 healthcare workers and 161 adults aged 20-60 years old and measured diphtheria antitoxin (DAT) level before administration of a Td vaccine. We scheduled a second Td at 4-8 weeks and a third Td at 6-12 months interval. DAT was measured 4 weeks after each dose. DAT levels of >= 0.1 and >= 1 IU/mL were considered as seroprotective and long-term seroprotective. Persons achieving long-term seroprotection were not given a further dose. The baseline seroprotection rate was 32.6%, which increased to 87.1% (95% confidence interval, 83.4-90.8%) after one dose. The seroprotection rate increased slightly with additional doses. The immune response was lowest among persons 30-49 years of age. We suggest 1-dose Td for adults during a diphtheria outbreak, and a 2-dose series being considered for those born before 1980. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2128 / 2131
页数:4
相关论文
共 10 条
  • [1] Immunogenicity and reactogenicity of a single dose of a diphtheria-tetanus-acellular pertussis component vaccine (DTaP) compared to a diphtheria-tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults
    Bartels, I
    Jüngert, J
    Lugauer, S
    Stehr, K
    Heininger, U
    VACCINE, 2001, 19 (23-24) : 3137 - 3145
  • [2] Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose
    Halperin, Scott A.
    Scheifele, David
    De Serres, Gaston
    Noya, Francisco
    Meekison, William
    Zickler, Paul
    Larrivee, Luc
    Langley, Joanne M.
    McNeil, Shelly A.
    Dobson, Simon
    Jordanov, Emilia
    Thakur, Manoj
    Decker, Michael D.
    Johnson, David R.
    VACCINE, 2012, 30 (05) : 974 - 982
  • [3] Immunogenicity and safety of a single intramuscular dose of a diphtheria-tetanus toxoid (Td) vaccine (GC1107) in Korean adults
    Lee, SeungHwan
    Park, Wan Beom
    Shin, Kwang-Hee
    Ahn, Dong Ho
    Yoon, Seo Hyun
    Cho, Joo-Youn
    Shin, Sang-Goo
    Jang, In-Jin
    Yu, Kyung-Sang
    VACCINE, 2011, 29 (44) : 7638 - 7643
  • [4] IMMUNOGENICITY AND SAFETY OF A SINGLE INTRAMUSCULAR DOSE OF A DIPHTHERIA-TETANUS TOXOID (TD) VACCINE (GC1107) IN KOREAN ADULTS
    Lee, S.
    Shin, K.
    Shin, D.
    Yoon, S.
    Cho, J.
    Yu, K.
    Shin, S.
    Jang, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S58 - S58
  • [5] Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose
    Halperin, Scott A.
    McNeil, Shelly
    Langley, Joanne
    Blatter, Mark
    Dionne, Marc
    Embree, Joanne
    Johnson, Roehl
    Latiolais, Thomas
    Meekison, William
    Noya, Francisco
    Senders, Shelly
    Zickler, Paul
    Johnson, David R.
    VACCINE, 2011, 29 (46) : 8459 - 8465
  • [6] PREVALENCE AND FACTORS ASSOCIATED WITH UPTAKE OF THE 3-DOSE CATCH-UP PRIMARY SERIES OF THE TETANUS-DIPHTHERIA VACCINE IN A RECENTLY RESETTLED REFUGEE POPULATION
    Voelker, J.
    Payton, C.
    Altshuler, M.
    Maio, V
    VALUE IN HEALTH, 2018, 21 : S158 - S158
  • [7] Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults
    Brandon, Donald
    Kimmel, Murray
    Kuriyakose, Sherine O.
    Kostanyan, Lusine
    Mesaros, Narcisa
    VACCINE, 2018, 36 (42) : 6325 - 6333
  • [8] Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand
    Fortuna, Librada
    Chaithongwongwatthana, Surasith
    Soonthornworasiri, Ngamphol
    Spiegel, Jane
    Wijagkanalan, Wassana
    Mansouri, Souad
    van den Biggelaar, Anita H. J.
    Pham, Hong Thai
    VACCINE, 2020, 38 (51) : 8194 - 8199
  • [9] Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults (vol 36, pg 6325, 2018)
    Brandon, Donald
    Kimmel, Murray
    Kuriyakose, Sherine O.
    Kostanyan, Lusine
    Mesaros, Narcisa
    VACCINE, 2020, 38 (12) : 2746 - 2747
  • [10] A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial
    Sricharoenchai, Sirintip
    Sirivichayakul, Chukiat
    Chokephaibulkit, Kulkanya
    Pitisuttithum, Punnee
    Dhitavat, Jittima
    Pitisuthitham, Arom
    Phongsamart, Wanatpreeya
    Boonnak, Kobporn
    Lapphra, Keswadee
    Sabmee, Yupa
    Wittawatmongkol, Orasri
    Chinwangso, Pailinrut
    Poredi, Indrajeet Kumar
    Petre, Jean
    Pham Hong Thai
    Viviani, Simonetta
    LANCET INFECTIOUS DISEASES, 2018, 18 (01): : 58 - 67